STAT

Pharma is making progress addressing global health, but it’s still a mixed bag

Drug makers are taking steps to reach people on very low incomes, but access programs are for just a few diseases.
Source: APStock

As the pharmaceutical industry confronts growing demands to improve global health and combat neglected diseases, a new analysis finds patchy progress as most efforts are undertaken by a handful of companies targeting only a few maladies in a small number of low and middle-income countries.

Drug makers taking steps to reach people on very low incomes and R&D pipelines have grown, but patient access programs have been confined to just a few diseases, only some companies are tackling the risks of unethical sales behavior, and still fewer support.

You're reading a preview, sign up to read more.

More from STAT

STAT7 min read
Once Widely Criticized, The Wuhan Quarantine Bought The World Time To Prepare For Covid-19
Early evidence is causing some public health experts to reconsider their initial scathing criticism of quarantines and travel restrictions intended to combat the novel coronavirus.
STAT5 min read
Opinion: Why We Need Mandatory Labeling Of GMO Products
Clear labels showing that foods containing #GMO or ingredients made from them isn't just about transparency. If done right, companies should be proud of the fact that they use genetic…
STAT4 min read
A Startup Aims To Reimagine The Executive Physical — With Silicon Valley Flourish And A $3,500 Price Tag
The three-martini lunch may be on the decline, but the "executive physical" is still offered to C-suite executives. Can a Silicon Valley startup make the exams accessible to a broader…